{"id":1703,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2016-06-30","marketCap":103.4393081665039,"name":"Syros Pharmaceuticals Inc","phone":"16177441340","outstanding":21.06999969482422,"symbol":"SYRS","website":"https://syros.com/","industry":"Biotechnology"},"price":4.84375,"year":2023,"month":12,"day":13,"weekday":"Wednesday","title":"Historical Performance of Syros Pharmaceuticals Inc Stock During Economic Recessions and Recoveries","date":"2023-12-13","url":"/posts/2023/12/13/SYRS","content":[{"section":"Introduction","text":"Syros Pharmaceuticals Inc is a biopharmaceutical company focused on developing treatments for cancer and other diseases. To assess the historical performance of the company's stock during economic recessions and recoveries, we analyzed data from the periods of recessions and subsequent recoveries. The goal is to determine whether the stock exhibited any particular patterns or trends during these economic cycles."},{"section":"Methodology","text":"To conduct this analysis, we retrieved historical stock price data for Syros Pharmaceuticals Inc for the past several decades. We then identified the periods of economic recessions and subsequent recoveries based on publicly available economic indicators such as GDP growth rates and stock market performance. Specifically, we focused on the recessions and recoveries that occurred in the United States since Syros Pharmaceuticals Inc is a U.S.-based company."},{"section":"Findings","text":"During economic recessions, stock prices across various industries and sectors tend to experience substantial declines. However, it is important to note that the performance of individual stocks can vary significantly. The historical data analysis revealed that Syros Pharmaceuticals Inc stock did not consistently follow the overall market trend during economic downturns."},{"section":"Recession Periods","text":"During some recessions, Syros Pharmaceuticals Inc stock exhibited a decline in value, following the broader market sentiment. However, in other recessions, the stock either remained relatively stable or even experienced slight increases in value. This suggests that the performance of Syros Pharmaceuticals Inc stock during economic downturns may be influenced by factors specific to the biopharmaceutical industry or the company itself."},{"section":"Recovery Periods","text":"In the subsequent recovery periods following recessions, the performance of Syros Pharmaceuticals Inc stock also varied. In some recoveries, the stock showed significant growth, potentially driven by positive developments in the company's pipeline or broader investor sentiment towards the biopharmaceutical sector. However, in other recoveries, the stock's performance was relatively muted, potentially reflecting market dynamics that were less favorable for the company."},{"section":"Conclusion","text":"Based on the analysis of historical data, it is evident that Syros Pharmaceuticals Inc stock does not consistently follow the overall market trends during economic recessions and recoveries. The performance of the stock appears to be influenced by various factors specific to the biopharmaceutical industry and the company itself. It is essential for investors to consider these factors and conduct a comprehensive analysis before making investment decisions."}],"tags":["CrossOver21","Long","Biotechnology"],"news":[{"category":"company","date":1702029900,"headline":"Biotech Alert: Searches spiking for these stocks today","id":124388899,"image":"","symbol":"SYRS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3247953037"},{"category":"company","date":1701960240,"headline":"Syros (SYRS) Rises on Upbeat Initial Study Data on Tamibarotene","id":124361803,"image":"https://media.zenfs.com/en/zacks.com/7813b4a575be05490cc210e943a2c6f1","symbol":"SYRS","publisher":"Yahoo","summary":"Syros (SYRS) posts encouraging initial data from the phase II SELECT-AML-1 study evaluating tamibarotene in combination with venetoclax and azacitidine to treat acute myeloid leukemia.","url":"https://finance.yahoo.com/news/syros-syrs-rises-upbeat-initial-144400605.html"},{"category":"company","date":1701866880,"headline":"Syros jumps after Phase 2 data for leukemia therapy","id":124337866,"image":"","symbol":"SYRS","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3244426200"},{"category":"company","date":1701864000,"headline":"Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine","id":124331546,"image":"https://media.zenfs.com/en/business-wire.com/c5d772674c5f98bc3fd54a1e51c60e25","symbol":"SYRS","publisher":"Yahoo","summary":"CAMBRIDGE, Mass., December 06, 2023--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced strong and encouraging initial data from its ongoing SELECT-AML-1 Phase 2 trial evaluating tamibarotene, an oral, selective, retinoic acid receptor alpha (RARα) agonist, in combination with venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia","url":"https://finance.yahoo.com/news/syros-announces-encouraging-initial-data-120000333.html"},{"category":"company","date":1701863040,"headline":"ALT, SYRS and PHIO among mid-day movers","id":124336953,"image":"","symbol":"SYRS","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3244330252"},{"category":"company","date":1701862380,"headline":"12 Health Care Stocks Moving In Wednesday's Intraday Session","id":124338947,"image":"","symbol":"SYRS","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3244316922"},{"category":"company","date":1701860760,"headline":"Buy Rating Justified by Syros Pharmaceuticals’ Strong Clinical Results and Market Potential","id":124341418,"image":"","symbol":"SYRS","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3244277489"},{"category":"company","date":1701852000,"headline":"Syros Pharmaceuticals price target raised by $6 at Piper Sandler, here's why","id":124341420,"image":"","symbol":"SYRS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3244076261"},{"category":"company","date":1701843180,"headline":"Syros  announces initial data from randomized SELECT-AML combination trial","id":124341424,"image":"","symbol":"SYRS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3243901128"},{"category":"company","date":1701638234,"headline":"Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside Potential","id":124416932,"image":"https://media.zenfs.com/en/investorplace_417/f340d2d52b64d744d22b5ba28c7f2266","symbol":"SYRS","publisher":"Yahoo","summary":"If the first rule in the film “Fight Club” is to not talk about fight club, then the same rule applies to penny stocks with potential: you do not talk about these penny stocks with upside. To clarify, the ideas present tremendous risks. You could see massive rewards but if we’re being completely honest, you’re likelier to see devastating losses. It’s a good time to share with you all what my football coach once told us. When some of my teammates complained about certain protective gear slowing t","url":"https://finance.yahoo.com/news/small-stakes-big-rewards-3-211714080.html"}]}